会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 6. 发明授权
    • Controlled-release preparations
    • 控制释放制剂
    • US5637319A
    • 1997-06-10
    • US396715
    • 1995-03-01
    • Kanji Takada
    • Kanji Takada
    • A61K9/00A61K9/48
    • A61K9/4808A61K9/0004Y10S514/962
    • The invention provides oral controlled-release preparations suitable to deliver drugs to different sites of gastrointestinal tract and suitable to control the release rate of drugs. As a first function, targeting of drugs to the lower part of the small intestine or colon is possible with two technologies. One is a time-controlled release system comprising adjusting the balance of the tolerability and thickness of a water-insoluble material membrane and the amount of a swellable substance. The other one is an intestinal pressure controlled-release system comprising adjusting the thickness of a water-insoluble material membrane. As a second function, by adjusting pore number, pore size and the amount of gel-forming substance, a sustained-release preparation of extremely water-soluble, hydrophilic, low-molecular weight drug is possible.
    • 本发明提供了适于将药物递送到胃肠道的不同部位并适于控制药物释放速率的口服缓释制剂。 作为第一个功能,可以通过两种技术将药物靶向小肠或结肠的下部。 一种是时间控制释放系统,其包括调节水不溶性材料膜的耐受性和厚度的平衡以及可溶胀物质的量。 另一种是肠调压释放系统,其包括调节水不溶性材料膜的厚度。 作为第二功能,通过调节孔数,孔径和形成凝胶的物质的量,可以使极端水溶性,亲水性,低分子量药物的缓释制剂。
    • 8. 发明授权
    • Preparation for body surface application and preparation for body surface application-holding sheet
    • 身体表面应用准备和身体表面施用保持片的准备
    • US08491534B2
    • 2013-07-23
    • US12734755
    • 2008-11-21
    • Kanji Takada
    • Kanji Takada
    • A61M5/00A61M37/00A61M5/32B28B11/08A61K9/00
    • A61K31/07A61K9/0021A61K9/703A61K31/196A61K31/375A61K31/404A61K31/4178A61K31/436A61K31/496A61K31/7048A61K31/727A61K38/21A61K47/36A61M37/0015A61M2037/0053Y02A50/465
    • It is an objective to provide a microneedle and a microneedle array formed from a self-dissolving base which can realize higher absorption efficiency and a higher pharmacological availability. A preparation 1 for body surface application has two sections divided in the insertion direction, namely, an acral portion 5 and a rear end portion 6. The acral portion 5 is a section including a body surface insertion end 2, and holds a target substance soluble in base. The rear end portion 6 is a section including a pressing end 3, and is formed mainly only from the base. The rear end portion 6 does not hold the target substance. When the preparation 1 for body surface application is inserted into a body surface such as the skin, since the target substance is contained in the acral portion 5, even if part of the rear end side thereof is subsequently not fully inserted into the body surface, high absorption efficiency and high pharmacological effect can be realized where the actual dose of the target substance is not below the desired amount of the drug.
    • 目的是提供一种由自溶碱形成的微针和微针阵列,其可以实现更高的吸收效率和更高的药理学可用性。 用于体表应用的制剂1在插入方向上具有两个部分,分别是顶端部分5和后端部分6.顶端部分5是包括体表插入端2的部分,并且保持目标物质可溶 在基地。 后端部6是包括按压端3的部分,并且仅主要由基部形成。 后端部6不保持目标物质。 当用于体表应用的制剂1插入到皮肤的体表中时,由于目标物质被容纳在头部5中,所以即使其后端侧的一部分后来没有完全插入体表中, 当目标物质的实际剂量不低于所需量的药物时,可以实现高吸收效率和高药理作用。
    • 9. 发明申请
    • MICRONEEDLE ASSEMBLY FORMULATION FOR SKIN TREATMENT
    • 用于皮肤治疗的MICRONEEDLE组装配方
    • US20130072902A1
    • 2013-03-21
    • US13696621
    • 2012-06-28
    • Kanji TakadaIchiro Ono
    • Kanji TakadaIchiro Ono
    • A61M37/00
    • A61M37/0015A61K9/0021A61K9/70A61K38/1825A61K45/06A61M2037/0046
    • A problem to be solved of the present invention is to provide a drug formulation and a method of administering an active ingredient which allow the active ingredient to be delivered evenly into the site of action in the skin with high efficiency while ensuring stability of the active ingredient over a long time, and which are easily handled and are less stressful for patients. Mean for solving the problem is a microneedle assembly formulation for skin treatment comprising a platform and a plurality of conical or pyramidal microneedles formed on the platform containing a base composed of a bio-soluble and thread-forming polymer substance and an objective substance retained in the base, wherein the objective substance is a substance effective for prevention or treatment of skin senescence, or treatment of skin scar.
    • 本发明要解决的问题是提供一种药物制剂和施用活性成分的方法,所述活性成分允许活性成分以高效率均匀地输送到皮肤中的作用部位,同时确保活性成分的稳定性 很长时间,容易处理,对患者压力较小。 解决问题的意思是用于皮肤处理的微针组装配方,其包括平台和形成在平台上的多个锥形或金字塔形微针,其包含由生物可溶和线形成聚合物物质组成的基质和保留在 碱,其中目标物质是有效预防或治疗皮肤衰老的物质,或治疗皮肤瘢痕。
    • 10. 发明申请
    • PREPARATION FOR BODY SURFACE APPLICATION AND PREPARATION FOR BODY SURFACE APPLICATION-HOLDING SHEET
    • 身体表面应用的准备和身体表面应用控制表的制备
    • US20110028905A1
    • 2011-02-03
    • US12734755
    • 2008-11-21
    • Kanji Takada
    • Kanji Takada
    • A61M5/00
    • A61K31/07A61K9/0021A61K9/703A61K31/196A61K31/375A61K31/404A61K31/4178A61K31/436A61K31/496A61K31/7048A61K31/727A61K38/21A61K47/36A61M37/0015A61M2037/0053Y02A50/465
    • It is an objective to provide a microneedle and a microneedle array formed from a self-dissolving base which can realize higher absorption efficiency and a higher pharmacological availability. A preparation 1 for body surface application has two sections divided in the insertion direction, namely, an acral portion 5 and a rear end portion 6. The acral portion 5 is a section including a body surface insertion end 2, and holds a target substance soluble in base. The rear end portion 6 is a section including a pressing end 3, and is formed mainly only from the base. The rear end portion 6 does not hold the target substance. When the preparation 1 for body surface application is inserted into a body surface such as the skin, since the target substance is contained in the acral portion 5, even if part of the rear end side thereof is subsequently not fully inserted into the body surface, high absorption efficiency and high pharmacological effect can be realized where the actual dose of the target substance is not below the desired amount of the drug.
    • 目的是提供一种由自溶碱形成的微针和微针阵列,其可以实现更高的吸收效率和更高的药理学可用性。 用于体表应用的制剂1在插入方向上具有两个部分,分别是顶端部分5和后端部分6.顶端部分5是包括体表插入端2的部分,并且保持目标物质可溶 在基地。 后端部6是包括按压端3的部分,并且仅主要由基部形成。 后端部6不保持目标物质。 当用于体表应用的制剂1插入到皮肤的体表中时,由于目标物质被容纳在头部5中,所以即使其后端侧的一部分后来没有完全插入体表中, 当目标物质的实际剂量不低于所需量的药物时,可以实现高吸收效率和高药理作用。